Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Clinical trial NCT00179621 · COMPLETED

Trial details

NCT number: NCT00179621
Sponsor: Celgene Corporation
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Myelodysplastic Syndromes

Start date: 2005-07-01
Primary completion: 2008-06-01
Enrollment: 205

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.